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1. INTRODUCTION {#cas14419-sec-0001}
===============

The cell cycle is precisely controlled by cyclin‐dependent kinases (CDKs) whose activities are regulated by interactions with the corresponding cyclin proteins. At the G~1~/S transition in normal cells, cyclin D is induced by mitogenic stimuli to form the CDK4/6‐cyclin D complex. This complex is transported to the nucleus, where it phosphorylates retinoblastoma (Rb) protein. This leads to release of the sequestered transcription factor E2F from Rb and activates transcription of E2F‐responsive genes required to drive the cell through the G~1~/S transition.[^1^](#cas14419-bib-0001){ref-type="ref"} Overexpression of cyclin D and CDK4/6, as well as constitutively active mutants of CDK4/6, has been detected in multiple types of human neoplasia.[^1^](#cas14419-bib-0001){ref-type="ref"} Therefore, CDK4/6 is considered to be an important target for cancer therapy.[^2^](#cas14419-bib-0002){ref-type="ref"}

The first CDK4/6‐specific inhibitor, palbociclib (PD‐0332991), was reported in 2004.[^3^](#cas14419-bib-0003){ref-type="ref"}, [^4^](#cas14419-bib-0004){ref-type="ref"} Over the next decade, the next CDK4/6 specific inhibitors ribociclib (LEE011) and abemaciclib (LY‐2835219) were developed,[^5^](#cas14419-bib-0005){ref-type="ref"}, [^6^](#cas14419-bib-0006){ref-type="ref"}, [^7^](#cas14419-bib-0007){ref-type="ref"} and many clinical trials have been performed for various neoplasia including non--small‐cell lung cancer, colon cancer, and breast cancer.[^8^](#cas14419-bib-0008){ref-type="ref"}, [^9^](#cas14419-bib-0009){ref-type="ref"} These inhibitors have been approved for breast cancer therapy by the FDA and the corresponding agencies in other countries.[^8^](#cas14419-bib-0008){ref-type="ref"}, [^9^](#cas14419-bib-0009){ref-type="ref"} In terms of the therapeutic mechanism in cancer cells, these inhibitors block CDK4/6‐cyclin D activity, leading to inhibition of Rb phosphorylation, which represses transcription of the genes associated with the G~1~/S transition.[^10^](#cas14419-bib-0010){ref-type="ref"} Thus, these inhibitors are considered to induce a cytostatic effect, rather than a cytocidal effect, in cancer cells.[^5^](#cas14419-bib-0005){ref-type="ref"}, [^6^](#cas14419-bib-0006){ref-type="ref"} However, the precise molecular mechanism of the antitumor effect remains to be elucidated.

The lysosome is a cytoplasmic organelle that constitutes the primary digestive compartment of the cell and plays important roles in endocytosis, phagocytosis, and autophagy.[^11^](#cas14419-bib-0011){ref-type="ref"}, [^12^](#cas14419-bib-0012){ref-type="ref"}, [^13^](#cas14419-bib-0013){ref-type="ref"} The luminal side of the lysosome maintains an acidic environment via the action of the vacuolar‐type ATPase (V‐ATPase), which functions as a proton pump across the lysosomal membrane. The lysosome contains more than 50 types of acid hydrolases including proteases, peptidases, nucleases, glycosidases, and lipases, which collectively are capable of digesting all types of macromolecules.[^14^](#cas14419-bib-0014){ref-type="ref"}, [^15^](#cas14419-bib-0015){ref-type="ref"} Disorders of lysosomal activities caused by defects in these enzymes or V‐ATPase component(s) induce many types of diseases, including lysosomal storage diseases, atherosclerosis, and Alzheimer\'s disease.[^14^](#cas14419-bib-0014){ref-type="ref"}, [^16^](#cas14419-bib-0016){ref-type="ref"}, [^17^](#cas14419-bib-0017){ref-type="ref"}, [^18^](#cas14419-bib-0018){ref-type="ref"}, [^19^](#cas14419-bib-0019){ref-type="ref"} In addition, the lysosome drives the progression of many types of human cancers through nutrient sensing by the lysosomal mTORC1 complex and nutrient scavenging by the autophagy system.[^20^](#cas14419-bib-0020){ref-type="ref"}, [^21^](#cas14419-bib-0021){ref-type="ref"}, [^22^](#cas14419-bib-0022){ref-type="ref"}, [^23^](#cas14419-bib-0023){ref-type="ref"}

In this study, we found that all 3 CDK4/6 inhibitors exert a cytocidal effect in cancer cell lines. Among them, abemaciclib exhibited the most potent cytotoxic effect and also induced a form of cell death whose phenotypic characteristics were not consistent with apoptosis, necroptosis, autophagic cell death, or methuosis. Instead, the dying cells formed multiple large cytoplasmic vacuoles derived from expanded lysosomes. Because inhibitors of the V‐ATPase almost completely inhibited vacuole formation, as well as repressing the cytocidal effect, we conclude that abemaciclib induces a novel type of cell death characterized by formation of cytoplasmic vacuoles.

2. MATERIALS AND METHODS {#cas14419-sec-0002}
========================

Cancer cell lines including the lung cancer cell line A549 and the breast cancer cell line MCF7 were cultured with abemaciclib, ribociclib, and palbociclib. Cytotoxic effect and cell‐death phenotype induced by these CDK4/6 inhibitors were examined by cell viability assay, cytotoxicity assay, cell morphology, cell‐cycle analysis, western blot analysis, autophagy flux assay, live‐cell imaging, immunofluorescent staining, and transmission electron microscopy. The details are shown in Appendix [S1](#cas14419-sup-0001){ref-type="supplementary-material"}.

3. RESULTS {#cas14419-sec-0003}
==========

3.1. Effects of CDK4/6 inhibitors on cell proliferation in A549 and MCF7 cells {#cas14419-sec-0004}
------------------------------------------------------------------------------

We first investigated the effect of CDK4/6 inhibitors on the CDK4/6 activity and the cell growth of the lung cancer cell line A549 and the breast cancer cell line MCF7. The phosphorylation state of Rb, which is one of the critical substrates of CDK4/6, was reduced in A549 cells treated with these CDK4/6 inhibitors (Figure [S1](#cas14419-sup-0001){ref-type="supplementary-material"}). A reduction in viable cell number was observed within 24 h in the presence of these inhibitors at concentrations on the order of 10‐100 µmol/L (Figure [1A‐D](#cas14419-fig-0001){ref-type="fig"}). Similar dose‐responses were seen in the cytotoxicity determined with lactate dehydrogenase (LDH) release assay (Figure [1E](#cas14419-fig-0001){ref-type="fig"}‐H) and propidium iodide (PI) staining assay (Figure [S2](#cas14419-sup-0001){ref-type="supplementary-material"}). In addition, the timing of cell death induced by these inhibitors became early in a dose‐dependent manner (Figure [S2](#cas14419-sup-0001){ref-type="supplementary-material"}). Among the 3 CDK4/6 inhibitors, abemaciclib was the most potent growth inhibitor (Figure [1A‐D](#cas14419-fig-0001){ref-type="fig"}, Table [S1](#cas14419-sup-0001){ref-type="supplementary-material"}). Cell‐cycle analysis revealed that these cells were partially arrested at the G~1~ phase after exposure to abemaciclib (control vs abemaciclib; 63.1 ± 2.77% vs 73.1 ± 3.47% at 24 h, 66.0 ± 2.20% vs 73.7 ± 2.28% at 48 h in A549, 51.13 ± 1.85 vs 55.72 ± 0.30 at 24 h, 52.33 ± 2.36 vs 61.14 ± 4.99 at 48 h in MCF7) (Figure [1I](#cas14419-fig-0001){ref-type="fig"}‐L). These results indicate that cell growth inhibition by these CDK4/6 inhibitors was due to not only a cytostatic effect but also a cytocidal effect.

![Effects of CDK4/6 inhibitors on proliferation of A549 and MCF7 cells. A‐D, A549 and MCF7 cells were treated with abemaciclib (Abe), ribociclib (Rib), or palbociclib (Pal) at indicated concentrations for 24 or 48 h. Cell viability was analyzed, and the number of viable cells cultured in control medium was defined as 100%. Data represent average values from 3 independent experiments. E‐H, A549 and MCF7 were treated with same conditions as in A‐D. Cytotoxicity was analyzed, and the number of total cells (viable and death cells) counted in each condition was defined as 100%. I‐L, A549 and MCF7 cells were treated with the indicated concentrations of Abe for 24 or 48 h. After fixation, cells were stained with PI, and the cell‐cycle profile was analyzed by flow cytometry using the ModFit LT 5.0 software. Representative data are shown (I, J). Data represent average values from 3 independent experiments and *P*‐values of *t* tests are indicated (K, L)](CAS-111-2132-g001){#cas14419-fig-0001}

3.2. Abemaciclib‐induced atypical cell death accompanied by cytoplasmic vacuole formation {#cas14419-sec-0005}
-----------------------------------------------------------------------------------------

To analyze the cell‐death phenotype, we next examined the morphological changes after treatment with CDK4/6 inhibitors at concentrations around the IC~50~ for 24 h (Table [S1](#cas14419-sup-0001){ref-type="supplementary-material"}). Many large cytoplasmic vacuoles were observed in A549 cells within 24 h of abemaciclib treatment (Figure [2A](#cas14419-fig-0002){ref-type="fig"}). Palbociclib induced smaller and fewer cytoplasmic vacuoles than abemaciclib, whereas ribociclib caused no vacuole formation (Figure [2A](#cas14419-fig-0002){ref-type="fig"}). Although abemaciclib induced cell death, neither adherent nor detached A549 cells contained nuclear fragments, chromatin condensation, or apoptotic bodies, all of which are characteristic features of cells undergoing apoptosis (Figure [2A,B](#cas14419-fig-0002){ref-type="fig"}). Similar morphological changes were observed in MCF7, CAL 27, and HT‐29 cells (Figure [S3](#cas14419-sup-0001){ref-type="supplementary-material"}), suggesting that abemaciclib induces non‐apoptotic cell death. Western blotting for proteins involved in induction of cell death revealed that, in abemaciclib‐treated A549 cells, poly(ADP‐ribose) polymerase (PARP) was cleaved but caspase‐3 was not cleaved much, indicating that the contribution of apoptosis to the observed cell death was scarce (Figure [2C](#cas14419-fig-0002){ref-type="fig"}). In addition, we detected no phosphorylation of receptor interacting protein 1 kinase 1 (RIPK1) and mixed lineage kinase domain‐like (MLKL) as determined using phosphorylation‐specific antibodies, and no phosphorylation of RIPK3 as determined by mobility shift in acrylamide gel; the phosphorylated states of these proteins indicate cells undergoing necroptosis[^24^](#cas14419-bib-0024){ref-type="ref"}, [^25^](#cas14419-bib-0025){ref-type="ref"}, [^26^](#cas14419-bib-0026){ref-type="ref"}, [^27^](#cas14419-bib-0027){ref-type="ref"} (Figure [2C](#cas14419-fig-0002){ref-type="fig"}). In A549 cells, abemaciclib‐induced cell death was partially rescued with small significant difference to control in the presence of either the pan‐caspase inhibitor Z‐VAD‐fmk or the necroptosis inhibitor necrostatin‐1 (Figure [2D](#cas14419-fig-0002){ref-type="fig"} top). These observations suggest that apoptosis and necroptosis make very minor contributions to abemaciclib‐induced cell death. Moreover, in contrast to thapsigargin treatment, a well known inducer of endoplasmic reticulum (ER) stress, there was no induction of the ER stress--related pro‐apoptotic transcription factor CCAAT‐enhancer‐binding protein homologous protein (CHOP)/GADD153 (Figure [2C](#cas14419-fig-0002){ref-type="fig"}).[^28^](#cas14419-bib-0028){ref-type="ref"} This also suggests that induction of cell death by abemaciclib was not mediated through ER stress loading. Additionally, *N*‐acetyl‐[l]{.smallcaps}‐cysteine, a reactive oxygen species (ROS) scavenger, had modest effect with significant difference to control abemaciclib‐induced cell death (Figure [2D](#cas14419-fig-0002){ref-type="fig"} bottom), suggesting that ROS did not play a major role in induction of cell death. Taken together, these data suggest that the cell‐death phenotype induced by abemaciclib does not correspond to apoptosis and necroptosis.

![Analysis of the cell‐death phenotype induced by abemaciclib. A, A549 cells were treated with Abe, Rib, or Pal for 24 h. After fixation, adherent cells on a cover glass were stained with May‐Grünwald‐Giemsa. B, A549 cells were treated with the indicated concentrations of Abe for 24 h. Detached and adherent cells were spread together on glass slides, and subsequently stained with May‐Grünwald‐Giemsa. Scale bars in A and B: 20 µm. C, A549 cells were treated with the indicated concentrations of Abe for 10 or 24 h. Cellular proteins were extracted and analyzed by western blotting using the indicated antibodies. "P‐" means "phosphorylated." As a positive control for apoptosis, CAL 27 cells were treated with 1 µmol/L staurosporine for 4 h. As a positive control for necroptosis, HT‐29 cells were pretreated with 20 µmol/L Z‐VAD‐fmk for 1 h, and subsequently treated with 10 µg/mL CHX and 10 ng/mL tumor necrosis factor‐α for 12 h (indicated as ZCT). As a positive control for ER stress, A549 cells were treated with 1 µmol/L thapsigargin for 24 h. D, A549 cells were treated with the indicated concentrations of Abe with or without 50 µmol/L Z‐VAD‐fmk, 50 µmol/L necrostatin‐1 (Nec‐1), necrostatin‐1 inactive control (IA‐Nec‐1), 10 mmol/L *N*‐acetyl‐[l]{.smallcaps}‐cysteine (NAC). After a 24‐h treatment, the viability was analyzed; the number of viable cells in samples treated with control medium containing the equivalent concentration of DMSO or buffer was defined at 100%. Data represent average values from 3 independent experiments. *P*‐values of *t* tests are indicated](CAS-111-2132-g002){#cas14419-fig-0002}

3.3. CDK4/6 inhibitors suppress autophagic flux {#cas14419-sec-0006}
-----------------------------------------------

It was reported that CDK4/6 inhibitors induce autophagy.[^29^](#cas14419-bib-0029){ref-type="ref"}, [^30^](#cas14419-bib-0030){ref-type="ref"}, [^31^](#cas14419-bib-0031){ref-type="ref"}, [^32^](#cas14419-bib-0032){ref-type="ref"}, [^33^](#cas14419-bib-0033){ref-type="ref"}, [^34^](#cas14419-bib-0034){ref-type="ref"}, [^35^](#cas14419-bib-0035){ref-type="ref"} Based on the results described above, we speculated that the prominent vacuole formation in response to abemaciclib might be related to autophagy. Western blotting revealed that microtubule‐associated protein light chain 3 (LC3B)‐II, a marker of autophagosomes, increased during a 1‐24‐h exposure to these inhibitors at concentrations near their IC~50~ in A549 cells (Figures [3A,B](#cas14419-fig-0003){ref-type="fig"} and [S4A](#cas14419-sup-0001){ref-type="supplementary-material"},[B](#cas14419-sup-0001){ref-type="supplementary-material"}), and p62/SQSTM1 increased during a 1‐24‐h exposure to abemaciclib and ribociclib (Figures [3A,B](#cas14419-fig-0003){ref-type="fig"} and [S4A](#cas14419-sup-0001){ref-type="supplementary-material"},[B](#cas14419-sup-0001){ref-type="supplementary-material"}). In addition, we performed autophagic flux assays using GFP‐LC3‐mCherry‐LC3ΔG probes in A549 cells.[^36^](#cas14419-bib-0036){ref-type="ref"} In this system, the probe is cleaved by endogenous ATG4 protease and produces the same amount of GFP‐LC3 and mCherry‐LC3ΔG. GFP‐LC3 is involved in autophagosome membrane formation via conjugation of phosphatidylethanolamine at the C‐terminal glycine residue. Subsequently, GFP‐LC3 is bleached and degraded by lysosomal hydrolases in an acidic environment via autolysosome formation during autophagic processing. In contrast to GFP‐LC3, mCherry‐LC3ΔG derived from the probe lacks the glycine residue and remains in the cytosol, serving as an internal control because it is exempt from lysosomal degradation. Therefore, autophagic flux can be monitored by the GFP/mCherry signal ratio.[^37^](#cas14419-bib-0037){ref-type="ref"} When the cells were cultured in HBSS, a starvation condition that induces autophagy, the GFP/mCherry ratio was indeed lower than in cells cultured in control medium whereas, in the presence of bafilomycin A1, a well known inhibitor of autophagy, the ratio was elevated. In addition, when autophagic flux was blocked by bafilomycin A1, prominent GFP‐LC3 dots (representing autophagosome accumulation) were detected, confirming the ability of this assay system to monitor autophagic flux (Figure [3C,D](#cas14419-fig-0003){ref-type="fig"}). As shown in Figure [3C](#cas14419-fig-0003){ref-type="fig"}, treatment with abemaciclib and ribociclib increased the GFP/mCherry ratio, indicating inhibition of autophagic flux. Consistent with this, both drugs caused accumulation of GFP‐LC3 dots, as in the case of bafilomycin A1 treatment (Figures [3D](#cas14419-fig-0003){ref-type="fig"} and [S4C](#cas14419-sup-0001){ref-type="supplementary-material"}). The GFP/mCherry ratio exhibited a biphasic curve over a 24‐h treatment period with palbociclib, which exerted a weaker effect on autophagy than abemaciclib (Figure [3C](#cas14419-fig-0003){ref-type="fig"}). Collectively, these results indicate that CDK4/6 inhibitors suppress autophagic flux in A549 cells. In addition, when we compared blocking of autophagic flux among the 3 CDK4/6 inhibitors at concentrations near the IC~50~ for cell growth, abemaciclib had the most prominent effect, as it did on formation of cytoplasmic vacuoles.

![Effects of CDK4/6 inhibitors on autophagic flux. A, B, A549 cells were treated with Abe at the indicated concentration for 24 h (A) or the indicated time periods (B). Western blotting used the indicated antibodies. Signal intensity of each band was quantified using CS Analyzer 4 software (ATTO), normalized by β‐actin, and is shown below. C, D, A549/GFP‐LC3‐mCherry‐LC3ΔG cells were cultured in the presence of the indicated reagents or culture medium, and fluorescence images were obtained on an IncuCyte ZOOM cell imaging system every hour over a 24‐h culture (D, green and red merged images at 0, 12, or 24 h, the images of cells treated by Rib and Pal are shown in Figure [S4C](#cas14419-sup-0001){ref-type="supplementary-material"}). The intensities of GFP‐LC3 and mCherry‐LC3ΔG in each field were measured using the same cell imaging system. The ratio of the fluorescence intensities of GFP and mCherry was calculated and expressed relative to the value from control cells cultured in control medium containing 0.5% DMSO. Data represent average values from 3 independent experiments (C). Scale bars in D: 20 µm](CAS-111-2132-g003){#cas14419-fig-0003}

3.4. Abemaciclib‐induced cell death and vacuole formation are suppressed by V‐ATPase inhibitors but independent of autophagy {#cas14419-sec-0007}
----------------------------------------------------------------------------------------------------------------------------

To examine the relationship between abemaciclib‐induced cell death and autophagy, we examined the effects of autophagy inhibitors on abemaciclib‐induced cell death using 3‐methyladenine, an inhibitor of class III PI3K, and bafilomycin A1 and concanamycin A, both of which are inhibitors of V‐ATPase. Abemaciclib‐induced cell death was rescued in the presence of bafilomycin A1 or concanamycin A (Figure [4A](#cas14419-fig-0004){ref-type="fig"} center and right), but not 3‐methyladenine (Figure [4A](#cas14419-fig-0004){ref-type="fig"} left). In addition, we established ATG5‐KO A549 cells. ATG5 is essential for modification of LC3B with phosphatidylethanolamine to form LC3B‐II, which is involved in autophagosome membrane formation. Consequently, ATG5‐KO cells are deficient in autophagy (Figure [4B](#cas14419-fig-0004){ref-type="fig"}). In these cells, abemaciclib still induced cell death that was attenuated by bafilomycin A1, as in control KO cells (Figure [4C](#cas14419-fig-0004){ref-type="fig"}). Moreover, abemaciclib‐induced vacuole formation was almost completely inhibited in the presence of bafilomycin A1 or concanamycin A (Figure [4D,E](#cas14419-fig-0004){ref-type="fig"}). Furthermore, in ATG5‐KO cells, abemaciclib induced vacuole formation, which was suppressed by bafilomycin A1 as in control KO cells (Figure [S5](#cas14419-sup-0001){ref-type="supplementary-material"}). These results indicate that vacuole formation is independent of autophagy. Taken together, these results indicate that the cell‐death phenotype induced by abemaciclib does not represent "autophagic cell death," a cell death phenotype characterized by excessive induction of autophagy.[^38^](#cas14419-bib-0038){ref-type="ref"} In addition, because bafilomycin A1 and concanamycin A, but not 3‐methyladenine, suppressed both cell death and vacuole formation by abemaciclib, we hypothesized that V‐ATPase is involved in this phenomenon.

![Inhibitory effects of V‐ATPase inhibitors in abemaciclib‐induced cell death and cytoplasmic vacuole formation. A, A549 cells were treated with the indicated concentrations of Abe with or without 3 nmol/L bafilomycin A1 (Baf), 1 nmol/L concanamycin A (ConcanA), or 1 mmol/L 3‐methyladenine (3‐MA). After a 24‐h treatment, the viability was analyzed; the number of viable cells in samples treated with control medium containing the equivalent concentration of DMSO or water was defined at 100%. Data represent average values from 3 independent experiments. *P*‐values of *t* tests are indicated. B, ATG5‐KO A549 cells were treated with or without 10 µmol/L Abe for 24 h, and subsequently analyzed by western blotting with the indicated antibodies. C, ATG5‐KO A549 cells were treated with the indicated concentrations of Abe and/or 3 nmol/L Baf. Data represent average values from 3 independent experiments. *P*‐values (*t* test) for +Baf vs −Baf samples are indicated above narrow lines, and *P*‐values for KO vs WT are indicated above bold lines. D, A549 cells were treated with the combination of Abe and 3 nmol/L Baf or 1 nmol/L ConcanA for 24 h. After fixation, adherent cells were stained with May‐Grünwald‐Giemsa. Scale bars: 20 µm. E, Number of vacuoles per cells of D was counted](CAS-111-2132-g004){#cas14419-fig-0004}

3.5. Most of cytoplasmic vacuoles induced by abemaciclib are derived from expanded lysosomes {#cas14419-sec-0008}
--------------------------------------------------------------------------------------------

To investigate the origin of cytoplasmic vacuoles induced by abemaciclib, we performed time‐lapse imaging of mCherry‐GFP‐LC3‐expressing A549 cells treated with abemaciclib (Figures [5A](#cas14419-fig-0005){ref-type="fig"} and [S6A](#cas14419-sup-0001){ref-type="supplementary-material"}, Movie [S1](#cas14419-sup-0001){ref-type="supplementary-material"}). In this system, because GFP is sensitive to acidic conditions, whereas mCherry is not, only the red fluorescent signal of mCherry is detectable after fusion of autophagosomes with lysosomes to form autolysosomes. Before abemaciclib treatment, we observed small red dots, indicating the basal state of the autolysosome (Figure [5A](#cas14419-fig-0005){ref-type="fig"}). After a 1‐h exposure to abemaciclib, many yellow dots derived from both GFP and mCherry (indicating autophagosomes) became detectable (Figure [5A](#cas14419-fig-0005){ref-type="fig"}, arrow), although most of them did not colocalized to vacuoles, and some small vacuoles contained mCherry red fluorescence only (indicating autolysosomes) (Figure [5A](#cas14419-fig-0005){ref-type="fig"}, indicated as arrowhead). Over time, as the vacuoles became larger and more numerous, only a subset contained the mCherry signal. Therefore, some but not all of the cytoplasmic vacuoles were derived from autolysosomes. As shown in Figure [4D,E](#cas14419-fig-0004){ref-type="fig"}, vacuole formation was suppressed by V‐ATPase inhibitors, so we speculated that abemaciclib‐induced vacuoles might be expanded lysosomes. To test this possibility, we next established an A549 cell line stably expressing lysosomal‐associated membrane protein (LAMP)1‐mCherry and performed time‐lapse imaging over a 24‐h exposure to abemaciclib (Figures [5B](#cas14419-fig-0005){ref-type="fig"} and [S6B](#cas14419-sup-0001){ref-type="supplementary-material"}, Movies [S2](#cas14419-sup-0001){ref-type="supplementary-material"} and [S3](#cas14419-sup-0001){ref-type="supplementary-material"}). In this assay, we also stained cells with LysoSensor Green DND‐189, which detects lysosomal acidification. The pKa of this LysoSensor Green is \~5.2. Before treatment with abemaciclib, we observed many small red dots (LAMP1‐mCherry) without green fluorescence (LysoSensor Green), suggesting that under basal conditions, the lysosomes were not acidic enough to stain with the acidification sensor. After 1 h of abemaciclib treatment, we observed some small vacuoles containing both LAMP1‐mCherry and LysoSensor Green fluorescence (Figure [5B](#cas14419-fig-0005){ref-type="fig"}, indicated as arrow). Of note, most of the vacuoles became larger (Figure [5B,C](#cas14419-fig-0005){ref-type="fig"}), and most of them stained with LysoSensor Green, and contained marginal localization of LAMP1‐mCherry; ultimately, some of the LysoSensor Green fluorescence disappeared (Figure [5B](#cas14419-fig-0005){ref-type="fig"}, indicated as arrowhead). These observations suggest that the swollen lysosomes became acidic and finally appeared to lose their function in response to abemaciclib treatment. At 12‐24 h after abemaciclib treatment, a few vacuoles appeared in which neither LAMP1‐mCherry nor LysoSensor Green was localized, suggesting that their origin was not lysosomes. In addition, to evaluate macropinocytosis,[^39^](#cas14419-bib-0039){ref-type="ref"}, [^40^](#cas14419-bib-0040){ref-type="ref"}, [^41^](#cas14419-bib-0041){ref-type="ref"} we assessed the uptake of fluorescent dextran into endosomes in the presence or absence of abemaciclib. In control cells, many green fluorescent dots caused by dextran uptake (indicating endosome) were observed and some of these dots colocalized to LAMP1‐mCherry dots (indicating lysosome) (Figure [S6C](#cas14419-sup-0001){ref-type="supplementary-material"}). Conversely, in abemaciclib‐treated cells, although fluorescent dextran dots were also observed, some of them were larger than that in control cells. Moreover, most fluorescent dextran did not co‐localize with abemaciclib‐induced vacuoles containing LAMP1‐mCherry (Figure [6](#cas14419-fig-0006){ref-type="fig"}). This suggests that most abemaciclib‐induced vacuoles are not derived from endosomes produced by macropinocytosis, indicating that abemaciclib‐induced cell death is not equivalent to methuosis, which is a cell‐death phenotype characterized by vacuole formation induced by excessive macropinocytosis.[^42^](#cas14419-bib-0042){ref-type="ref"}, [^43^](#cas14419-bib-0043){ref-type="ref"}, [^44^](#cas14419-bib-0044){ref-type="ref"}

![Analysis of cytoplasmic vacuole formation induced by abemaciclib. A, A549/mCherry‐GFP‐LC3 cells were treated with 10 µmol/L Abe and subjected to time‐lapse imaging. Merged fluorescence and bright‐field images (top) are presented for each time point. Arrowheads indicate red vacuoles; arrows indicate yellow dots not colocalized to vacuoles. Bottom 5 line panels represent high‐magnification images of the area indicated by open squares; merge, bright field, red (mCherry), green (GFP), and merge of red and green from the top. A movie generated from images collected at 10‐min intervals is presented as Movie [S1](#cas14419-sup-0001){ref-type="supplementary-material"}. B, A549/LAMP1‐mCherry cells cultured with 200 nmol/L LysoSensor Green DND‐189 were cultured in the presence or absence of 10 µmol/L Abe and subjected to time‐lapse imaging. Merged fluorescence and bright‐field images (top) are presented for each time point. Arrows indicate vacuoles with red and green fluorescence, arrowheads indicate vacuoles with marginal red fluorescence alone. Bottom 5 lines panels represent high‐magnification images of the area indicated by open squares; merge, bright field, red (LAMP1‐mCherry), green (LysoSensor Green), and merge of red and green from the top. Movies generated from images of Abe‐presence condition collected at 10‐min intervals are presented as Movie [S2](#cas14419-sup-0001){ref-type="supplementary-material"} (merged with fluorescence and bright‐field images) and Movie [S3](#cas14419-sup-0001){ref-type="supplementary-material"} (merged with red and green fluorescence images). In A and B, scale bars: 5 µm. The images not treated with Abe are presented as Figure [S6A,B](#cas14419-sup-0001){ref-type="supplementary-material"}. C, The cells were cultured in the presence of Abe with or without 3 nmol/L Baf (shown in Figure [5B](#cas14419-fig-0005){ref-type="fig"} or not shown). Diameter of lysosome (green and yellow signal) in these cells at 0 or 24 h were quantitated using ImageJ software (1.50i, National Institutes of Health, USA). Data represent average values of at least 100 lysosomes. *P*‐values of *t* tests are indicated](CAS-111-2132-g005){#cas14419-fig-0005}

![Analysis of relationship between endosomes and cytoplasmic vacuoles induced by abemaciclib. A549/LAMP1‐mCherry cells were cultured with 50 µmol/L fluorescent dextran and 10 µmol/L Abe for 8 h. Observation was performed after dextran was removed. Arrows indicate LAMP1‐mCherry localizing lysosome, and arrowheads indicate Alexa488‐dextran localizing endosomes. Bottom represents high‐magnification images of the area indicated by open squares. Scale bars: 5 µm. The images not treated with Abe are presented as Figure [S6C](#cas14419-sup-0001){ref-type="supplementary-material"}](CAS-111-2132-g006){#cas14419-fig-0006}

3.6. Abemaciclib induces lysosomal dysfunction which appears to be responsible for cell death execution {#cas14419-sec-0009}
-------------------------------------------------------------------------------------------------------

Finally, to investigate the mechanism of abemaciclib‐induced cell death, we examined the effects of abemaciclib on lysosome function. Transmission electron microscopy revealed that, in addition to enlarging, the vacuoles became more abundant during a 24‐h exposure to abemaciclib (Figure [7A](#cas14419-fig-0007){ref-type="fig"}). Most of these expanded vacuoles contained indigestible debris and remnants of organelles. This vacuolar "indigestion" persisted for at least 24 h during exposure to abemaciclib, supporting the idea that the vacuoles were derived from dysfunctional lysosomes (Figure [7A](#cas14419-fig-0007){ref-type="fig"}, lower panels). The mitochondria, ER, and nucleus were intact in abemaciclib‐treated cells, indicating that the target of abemaciclib is lysosome rather than any of the other organelles. To analyze lysosomal turnover, we performed a cycloheximide (CHX) chase assay in the presence or absence of abemaciclib. When A549 cells were treated with CHX, lysosomal membrane proteins (LAMP1, 2) and proteasome‐substrate protein (cyclin B) were degraded in a time‐dependent manner (Figure [7B,C](#cas14419-fig-0007){ref-type="fig"}). However, when treating with CHX and abemaciclib, degradation of only lysosomal membrane proteins was blocked (Figure [7B,C](#cas14419-fig-0007){ref-type="fig"}), suggested that abemaciclib disrupted lysosomal turnover. Next, to assess the lysosomal function as a platform for nutrient sensing and metabolic signal transduction through the mTORC1 protein kinase complex,[^20^](#cas14419-bib-0020){ref-type="ref"}, [^45^](#cas14419-bib-0045){ref-type="ref"}, [^46^](#cas14419-bib-0046){ref-type="ref"} we examined the mTORC1 activity in abemaciclib‐treated cells. The level of phospho‐mTOR kinase (active form of mTOR) and downstream effectors of mTORC1 signaling (phosphorylation of p70 S6 kinase and S6 ribosomal protein) were suppressed by abemaciclib treatment in a time‐dependent manner (Figure [7D](#cas14419-fig-0007){ref-type="fig"}). This suggests that abemaciclib impairs the lysosomal function as a platform of mTORC1 signaling. Furthermore, we evaluated lysosomal membrane permeabilization (LMP) by observation of galectin‐3 localization.[^47^](#cas14419-bib-0047){ref-type="ref"} In nontreated cells, galectin‐3 was diffused in cytosol (Figure [S7A](#cas14419-sup-0001){ref-type="supplementary-material"}, top). As a positive control for LMP, treatment with [l]{.smallcaps}‐leucyl‐[l]{.smallcaps}‐leucine methyl ester (LLOMe), a well known inducer for LMP, resulted in translocation and puncta formation of galectin‐3 on the damaged lysosomes (containing LAMP2) (Figure [S7A](#cas14419-sup-0001){ref-type="supplementary-material"}, bottom).[^47^](#cas14419-bib-0047){ref-type="ref"}, [^48^](#cas14419-bib-0048){ref-type="ref"} After treatment with abemaciclib at 10 µmol/L for 24 h, galectin‐3 puncta colocalized to lysosomes were observed in 32% of the cells. However, the number of galectin‐3 puncta in abemaciclib‐treated cells was lower than that in LLOMe‐treated cells (Figure [S7A](#cas14419-sup-0001){ref-type="supplementary-material"} middle 2 lines, B). This suggested that LMP was modestly increased by abemaciclib. Additionally, an increase in intracellular calcium concentration, which has been reported to be increased in response to LMP,[^49^](#cas14419-bib-0049){ref-type="ref"} was observed after 24 h treatment with abemaciclib (Figure [S8A,B](#cas14419-sup-0001){ref-type="supplementary-material"}), although we could not detect a prominent increase of intracellular calcium concentration by 4 h treatment with LLOMe (Figure [S8C,D](#cas14419-sup-0001){ref-type="supplementary-material"}). Taken together, our data suggest that abemaciclib treatment induces lysosomal dysfunction, concomitant with prominent lysosomal expansion and low levels of LMP, which appears to be responsible for cell‐death execution.

![Analyses of lysosomal dysfunctions treated by abemaciclib. A, A549 cells were treated with 10 µmol/L Abe for the indicated time periods. After fixation, the cells were observed by transmission electron microscopy. Bottom images represent higher magnifications of the areas indicated by open squares in the upper row. Mt: mitochondrion, N: nucleus, V: vacuole. Scale bars in upper row: 5 µm, Scale bars in lower row: 500 nm. B, A549 cells were treated with 500 µmol/L CHX in the presence or absence of 10 µmol/L Abe for the indicated time periods. Cellular proteins were extracted and analyzed by western blotting using the indicated antibodies. C, Signal intensity of each band of (B) was quantified using CS Analyzer 4 software, normalized by α‐tubulin. In each condition, signal intensity at 0 h was defined at 1. Data represent average values from 3 independent experiments. *P*‐values of *t* tests are indicated. D, A549 cells were treated with 10 µmol/L Abe for the indicated time periods. Cellular proteins were extracted and analyzed by western blotting using the indicated antibodies. S6K: S6 kinase; S6RP: S6 ribosomal protein. "P‐" means "phosphorylated." As a control for western blotting, cell lysate of HEK293 cells was used](CAS-111-2132-g007){#cas14419-fig-0007}

4. DISCUSSION {#cas14419-sec-0010}
=============

In this study, we revealed that abemaciclib induces atypical cell death associated with formation of cytoplasmic vacuoles derived from swollen lysosomes (Figures [1](#cas14419-fig-0001){ref-type="fig"},[2](#cas14419-fig-0002){ref-type="fig"}, and [5](#cas14419-fig-0005){ref-type="fig"}); this effect was almost completely inhibited in the presence of V‐ATPase inhibitors (Figure [4D,E](#cas14419-fig-0004){ref-type="fig"}). Transmission electron microscopy revealed that these vacuoles contained undigested remnants of organelles (Figure [7A](#cas14419-fig-0007){ref-type="fig"}). Thus, abemaciclib might act directly or indirectly on V‐ATPase, leading to lysosomal acidification via H^+^ transport (Figure [5B](#cas14419-fig-0005){ref-type="fig"}). This effect on V‐ATPase appears to induce lysosomal swelling via influx of H~2~O, as well as lysosomal dysfunction followed by LMP and an increase of intracellular calcium concentration (Figures [7](#cas14419-fig-0007){ref-type="fig"}, [S7](#cas14419-sup-0001){ref-type="supplementary-material"}, and [S8](#cas14419-sup-0001){ref-type="supplementary-material"}, summarized in Figure [8](#cas14419-fig-0008){ref-type="fig"}). Because V‐ATPase inhibitors also inhibited the cytotoxic effect of abemaciclib (Figure [4](#cas14419-fig-0004){ref-type="fig"}), loss of lysosomal integrity appeared to be closely related to the cytotoxicity of abemaciclib.

![Model of lysosomal expansion in response to abemaciclib treatment. Abe might directly or indirectly target V‐ATPase, which activates H^+^ transport, leading to lysosomal acidification followed by H~2~O influx. This induces lysosomal swelling, as well as lysosomal dysfunction, and ultimately results in induction of cell death via a novel molecular mechanism](CAS-111-2132-g008){#cas14419-fig-0008}

The phenotype we observed is superficially similar to methuosis, a form of cell death characterized by formation of multiple cytoplasmic vacuoles derived from endosomes via facilitation of macropinocytosis.[^42^](#cas14419-bib-0042){ref-type="ref"}, [^43^](#cas14419-bib-0043){ref-type="ref"}, [^44^](#cas14419-bib-0044){ref-type="ref"} However, fluorescent dextran taken up into endosomes via macropinocytosis did not extensively co‐localize with most of the abemaciclib‐induced vacuoles containing LAMP1‐mCherry (Figures [6](#cas14419-fig-0006){ref-type="fig"} and [S6C](#cas14419-sup-0001){ref-type="supplementary-material"}), indicating that cell‐death phenotype induced by abemaciclib is distinct from methuosis. Recently, LMP has come to be recognized to induce many types of cell death.[^47^](#cas14419-bib-0047){ref-type="ref"} Cationic materials, such as gold nanoparticle, have been shown to induce the rupture of lysosomal compartments through the lysosomal swelling, named proton sponge effect, and subsequently induce apoptosis via the massive calcium influx into the cells caused by lysosomal rupture.[^49^](#cas14419-bib-0049){ref-type="ref"} In our data, time‐lapse imaging revealed that during a 24‐h exposure to abemaciclib, most expanding lysosomes were unruptured (Movies [S1](#cas14419-sup-0001){ref-type="supplementary-material"} and [S2](#cas14419-sup-0001){ref-type="supplementary-material"}), and immunostaining of galectin‐3 exhibited that LMP induction was modest and limited (Figure [S7](#cas14419-sup-0001){ref-type="supplementary-material"}). The intracellular calcium concentration was increased by abemaciclib, while the cells treated with LLOMe with potent LMP inducibility resulted in a small increment (Figure [S8](#cas14419-sup-0001){ref-type="supplementary-material"}). Therefore, although the increased intracellular calcium concentration by abemaciclib might be involved in cell‐death execution, it is unlikely that the increment of the calcium concentration is due to LMP. Thus, the cell‐death phenotype induced by abemaciclib appears to be distinct from that observed with cationic materials.[^49^](#cas14419-bib-0049){ref-type="ref"} However, the cytoplasmic release of lysosomal hydrolyzes including cathepsins might be involved in cell death execution even though most expanding lysosomes were unruptured.

Our data also suggest that the target of abemaciclib relevant to vacuole formation is V‐ATPase rather than CDK4/6 (Figure [4D,E](#cas14419-fig-0004){ref-type="fig"}). All 3 CDK4/6 inhibitors inhibited Rb phosphorylation (Figure [S1](#cas14419-sup-0001){ref-type="supplementary-material"}). However, it was noteworthy that only abemaciclib induced prominent cytoplasmic vacuolization derived from lysosome along with prominent cytotoxicity (Figure [2A](#cas14419-fig-0002){ref-type="fig"}). This suggests that, unlike other CDK4/6 inhibitors, only abemaciclib acts on the V‐ATPase that may cause all unique phenotypes shown here. Brown et al reported accelerated induction of autophagy in cells lacking cyclin D1 due to either gene mutation or knockdown.[^29^](#cas14419-bib-0029){ref-type="ref"} By contrast, in this study, abemaciclib did inhibit autophagic flux (Figure [3](#cas14419-fig-0003){ref-type="fig"}). This observation also supports the idea that a target or targets other than CDK4/6 contribute to lysosomal dysfunction. Several previous studies reported induction of autophagy in response to CDK4/6 inhibitors.[^29^](#cas14419-bib-0029){ref-type="ref"}, [^30^](#cas14419-bib-0030){ref-type="ref"}, [^31^](#cas14419-bib-0031){ref-type="ref"}, [^32^](#cas14419-bib-0032){ref-type="ref"}, [^33^](#cas14419-bib-0033){ref-type="ref"}, [^34^](#cas14419-bib-0034){ref-type="ref"}, [^50^](#cas14419-bib-0050){ref-type="ref"} In this study, we sequentially monitored autophagic flux using fluorescence probe[^37^](#cas14419-bib-0037){ref-type="ref"}; this analysis revealed that all 3 CDK4/6 inhibitors tested inhibited autophagic flux at early time points. Only palbociclib yielded a biphasic curve in the GFP/mCherry ratio over 24‐h treatment (Figure [3](#cas14419-fig-0003){ref-type="fig"}). Therefore, the controversy regarding induction vs inhibition of autophagy might be due to differences between studies in exposure time or cell type. However, abemaciclib treatment caused accumulation of mCherry‐GFP‐LC3 dots (Figure [5A](#cas14419-fig-0005){ref-type="fig"}), as well as GFP‐LC3 dots, as in the case of bafilomycin A1 (Figure [3D](#cas14419-fig-0003){ref-type="fig"}), indicating that inhibition might occur at a late stage of autophagic processing, eg, autolysosome formation. In addition, transmission electron microscopy revealed that lysosomal vacuoles contained undigested debris, also supporting the idea of lysosomal dysfunction (Figure [7A](#cas14419-fig-0007){ref-type="fig"}). Furthermore, CHX chase assay revealed that lysosomal membrane protein degradation was blocked by abemaciclib (Figure [7B,C](#cas14419-fig-0007){ref-type="fig"}), suggesting disruption of lysosomal turnover caused by dysfunction. In addition to its role in cellular catabolism, the lysosome functions as a platform for nutrient sensing and metabolic signal transduction through the mTORC1 protein kinase complex. Signaling from the lysosomal surface, mTORC1 transduces downstream anabolic pathways, resulting in promotion of cell growth; therefore, abnormal mTORC1 nutrient sensing could cause cancer cell proliferation.[^20^](#cas14419-bib-0020){ref-type="ref"}, [^45^](#cas14419-bib-0045){ref-type="ref"}, [^46^](#cas14419-bib-0046){ref-type="ref"} In this study, mTORC1 activity was inhibited by abemaciclib treatment (Figure [7D](#cas14419-fig-0007){ref-type="fig"}), and cytoplasmic vacuole formation and cell death induced by abemaciclib were independent of the autophagic catabolic process, implying that inhibition of anabolic signaling from the lysosomal mTORC1 complex might be related to these cellular phenotypes of abemaciclib.

In conclusion, we showed that abemaciclib induces an atypical cell‐death phenotype characterized by lysosomal vacuolation. Because swelling of lysosomes appears to be closely linked with the more potent cytocidal effect of abemaciclib relative to palbociclib and ribociclib, future studies should seek to identify the target of abemaciclib responsible for lysosomal swelling, as well as the factors involved in execution of this unique form of lysosome‐related cell death. Such knowledge would further clarify the indications and usage of combination therapy for abemaciclib in cancer therapy.
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